Omeros Corp (OMER, Financial) experienced a notable stock price increase of 5.02%, reaching $11.92 per share with a trading volume of 457,702 shares and a turnover rate of 0.79%. The stock's amplitude was 7.65%. Despite reporting zero revenue and a net loss of $37.11 million, with an EPS of -$0.56 and a gross profit of -$237,000, the company's P/E ratio stood at -5.17.
Among the three institutions rating the stock, 33% recommended buying, while 67% suggested holding. Omeros operates in the biotechnology sector, which saw a modest overall increase of 0.04%. Notable stocks in the same sector included Senti Biosciences, Purple Biotech, and Cingulate Inc, with significant gains and high turnover rates.
Omeros Corp is a clinical-stage biopharmaceutical company focused on developing therapies for immune diseases, including narsoplimab (OMS721), targeting complement-mediated conditions.
